Related Experiment Video
Updated: Jan 16, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Personal approach for cancer treatment: A meta-analysis of Phase II clinical trials
Mikhail B Potievskiy1, Elena P Zharova1, Lidia A Nekrasova1
1FSBI "National Medical Research Radiological Center" of the Ministry of Health of the Russian Federation (FSBI "NMRRC"), Obninsk, Russia.
Background:
To date, no meta-analysis has studied the general outcomes of personalized cancer drug therapy with a focus on current targeted, immunotherapy, and multi-agent phase II clinical trials.
Objective:
We conducted a systematic review and meta-analysis to provide a comprehensive overview of outcomes in patients undergoing personalized genomics-based versus non-personalized treatment in oncology.
Data Source:
We searched for publications in PubMed, dedicated to specific cancer drug treatment and phase II clinical trials, and published from 2010 to 2021. The search dates were from 20.10.23 to 20.11.23. The final data check was on 20.12.23.
Selection Criteria:
Studies of chemotherapy, immunotherapy, and targeted therapy were included. Only trials, including adults (more than 18 y.o.) were selected. The personalization was evaluated based on genetic markers and study design.
Data Collection And Analysis:
The study was performed following PRISMA guidelines. Two reviewers worked independently to select studies and arms, and one checked the results. Three reviewers extracted the data, and another reviewer independently checked it. The proportional meta-analysis, random-effects model, and meta-regression were employed to evaluate the effects of genomics-based personalization and other study design parameters (randomization, multi-central protocol, pre-treatment, therapy type, number of patients per arm, and journal impact factor) on the treatment outcomes. Mann-Whitney was employed to compare survival medians, p < 0.05.
Results:
We evaluated 50 studies, having 81 arms and 6536 patients. Response Rate (RR) and 1-year Progression-Free Survival (PFS) were significantly higher in personalized arms (p = 0.009 and p = 0.011). Medians of PFS and Overall Survival (OS) were also higher in personalized arms (p = 0.018 and p = 0.032). Proportional meta-analysis and meta-regression detected a significant positive association between personalized treatment and RR (p = 0.037). The same results were obtained for 1-year PFS and OS rates (p = 0.043 and p = 0.022). Previous drug treatment, type of therapy (targeted therapy/immunotherapy/cytotoxic chemotherapy), study design, and journal impact factor did not affect RR, PFS, and OS. Personalization only affected the treatment outcomes.
Conclusion:
This study discovered the benefits of a personal approach to cancer treatment using genomic data. The personalized approach improved cancer outcomes and offers promising therapeutic potential for the further development of cancer treatment.
Registration:
PROSPERO record ID CRD42024504021.
Insights
Personalized cancer treatment using genomic data significantly improves response rates and survival outcomes. This approach enhances therapeutic potential for future cancer care strategies.
Area of Science:
- Oncology
- Genomics
- Clinical Trials
Background:
- No prior meta-analysis has comprehensively assessed outcomes of personalized cancer drug therapy in phase II trials.
- Focus on targeted therapy, immunotherapy, and multi-agent treatments.
Purpose of the Study:
- To conduct a systematic review and meta-analysis of personalized genomics-based versus non-personalized cancer treatment outcomes.
- Evaluate the impact of personalization on patient response and survival.
Main Methods:
- Systematic search of PubMed for phase II clinical trials (2010-2021).
- Inclusion of chemotherapy, immunotherapy, and targeted therapy trials in adults.
- PRISMA guidelines followed; data extracted and analyzed using proportional meta-analysis, random-effects model, and meta-regression.
Main Results:
- 50 studies (81 arms, 6536 patients) analyzed.
- Personalized treatment arms showed significantly higher Response Rates (RR) and 1-year Progression-Free Survival (PFS).
- Personalized treatment arms also demonstrated higher median PFS and Overall Survival (OS).
Conclusions:
- Genomic data-driven personalized cancer treatment offers significant benefits.
- Personalization positively impacts key treatment outcomes, including RR, PFS, and OS.
- This approach holds promising therapeutic potential for advancing cancer care.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:21Cancer Survival Analysis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:27Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...